Non-invasive ventilation in the treatment of acute and chronic exacerbated respiratory failure: What to expect outside the critical care units?  by Brandão, M.E. et al.
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on-invasive ventilation in the
reatment of acute and chronic
xacerbated respiratory
ailure: What to expect outside
he critical care units?
ear  Editor,
on-invasive  ventilation  (NIV)  undoubtedly  brings  beneﬁts  to
he  management  of  patients  with  acute  respiratory  failure.
lthough  the  number  of  indications  has  expanded  rapidly
ue  to  increasing  conﬁdence  in  managing  the  technique,  the
ptimal  location  for  using  NIV  is  still  a  matter  of  debate1,2.
Table  1  Demographic  and  baseline  clinical  characteristics
of the  study  group  (n  =  75).
Characteristics  Number  ±  SD  (or  %)
Mean  age  (years)  72  ±  11.3
Male sex  41  (54.7%)
Smoking  historya 39  (52%)
LTOT 47  (62.7%)
Domiciliary  NIV  13  (17.3%)
Hypercapnic  respiratory  failure 68  (90.7%)
Indication  for  NIV
AECOPD  42  (56%)
COPD/Sleep  apnea  overlap  syndrome 12  (16%)n
N
N
m
c
w
N
8
p
ohe  vast  majority  of  published  evidence  is  based  on  studies
onducted  in  highly  controlled  settings  such  as  respiratory
ntermediate  care  units  (RICU)  and  intensive  care  units
ICU).  These  outcomes  may  not  always  be  representative
f  everyday  practice  since  the  strict  criteria  used  to  select
atients  may  result  in  the  exclusion  of  the  more  elderly  and
hose  with  major  comorbidities.  However,  as  RICU/ICU  beds
re  limited  in  most  countries,  use  of  NIV  in  respiratory  wards
ay  be  an  appropriate  solution  in  selected  cases,  resulting
n  better  resource  utilization.
In  Portugal,  there  is  limited  data  available  on  the  use  of
IV  outside  the  RICU/ICU.3
The  purpose  of  this  letter  is  to  report  on  our  expe-
ience  with  ward-based  NIV  in  the  treatment  of  acute
nd  chronic  exacerbated  respiratory  failure.  We  retro-
pectively  analyzed  demographic  and  clinical  data  of  all
atients  who  had  had  a  NIV  trial  in  our  respiratory  ward
uring  a  two-year  period  (2012--2013).  Multivariate  anal-
sis  was  performed  on  age,  sex,  pH  and  PaCO2 before
IV,  FEV1  and  number  of  exacerbations  in  the  previous
ear,  to  identify  predictors  of  prolonged  ventilation  time
ventilatory  support  for  more  than  9  days)  or  NIV  fail-
re  (need  for  endotracheal  intubation  or  death).  Elective
dmissions  for  setting  up  domiciliary  NIV  and  patients
reated  with  Continuous  Positive  Airway  Pressure  were
xcluded.
During  the  study  period,  75  admissions  were  included,
hich  corresponded  to  65  patients,  mostly  male  (54.7%)
ith  a  mean  age  of  age  72  ±  11.3  years.  The  demographic
nd  clinical  characteristics  of  all  patients  are  summarized
n  Table  1.  In  the  subgroup  of  chronic  obstructive  pulmonary
isease  (COPD)  patients,  the  mean  FEV1  was  42.7  ±  16.3%
f  predicted,  and  57%  had  had  fewer  than  2  exacerbations
equiring  hospitalization  in  the  previous  year.
At  the  time  of  admission,  hypercapnic  respiratory  fail-
re  was  predominant  (90.7%),  with  a  mean  pH  before
IV  of  7.29  ±  0.10.  The  most  frequent  indication  for  NIV
as  acute  exacerbation  of  COPD  (AECOPD,  56%),  followed
y  exacerbation  of  COPD/sleep  apnea  overlap  syndrome
16%),  pneumonia  (6.7%),  obesity  hypoventilation  syn-
rome  decompensation  (5.3%),  acute  cardiogenic  pulmonary
dema  (4%)  and  respiratory  failure  in  neuromuscular  dis-
ase  (4%).  In  4%  of  cases,  NIV  was  used  as  part  of  ventilator
eaning  strategy.
The  median  time  under  NIV  was  9  days  (the  cut-off  used
o  deﬁne  prolonged  ventilation  time)  and  the  median  hos-
ital  length  of  stay  was  14  days.  The  ventilation  time  did
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wPneumonia  5  (6.7%)
OHS 4  (5.3%)
ACPE  3  (4%)
Neuromuscular  disease  3  (4%)
Ventilator  weaning  3  (4%)
Otherb 3  (4%)
Mean  arterial  blood  gases  prior  to  NIV
pH
Hypercapnic  patients  7.29  ±  0.10
Non-hypercapnic  patients  7.43  ±  0.05
PaO2 (mmHg)
Hypercapnic  patients  57  ±  34
Non-hypercapnic  patients  56  ±  13
PaCO2 (mmHg)
Hypercapnic  patients  73  ±  22
Non-hypercapnic  patients  38  ±  9
Patients  coming  from
Emergency  department  57  (76%)
Intensive/intermediate  care  unit  18  (22.8%)
ACPE, acute cardiogenic pulmonary edema; AECOPD, acute
exacerbation of chronic obstructive pulmonary disease; COPD,
chronic obstructive pulmonary disease; LTOT, long-term oxygen
therapy; NIV, non-invasive ventilation; OHS, obesity hypoventi-
lation syndrome.
a Current or former smokers.
b Other conditions: acute respiratory distress syndrome and
multifactorial hypoventilation.
ot  differ  between  groups  according  to  previous  domiciliary
IV  use.  In  14  NIV-trials  (18.7%),  adverse  effects  related  to
IV  were  reported,  most  frequently  nasal  bridge  ulcers  and
ucosal  dryness.  None  of  these  complications  caused  pro-
edure  withdrawal.  NIV  failed  in  eight  patients  (10.7%):  two
ere  intubated  and  six  died.  Half  of  the  failures  were  on
IV  for  AECOPD.  The  mortality  rate  in  the  study  sample  was
%.  The  causes  of  death  were  pneumonia  (n  =  4)  and  decom-
ensation  of  comorbidities  in  patients  with  do-not  intubate
rders  (n  =  2).
Among  the  variables  studied,  none  was  a  predictor  of
rolonged  ventilation  time  either  in  the  global  sample  of
atients  or  in  the  subgroup  of  AECOPD.  The  pretreatment
H  was  an  independent  predictive  factor  for  NIV  failure  in
he  overall  population  (OR  0.92;  CI  95%  0.85--0.99;  p  =  0.034)
Table  2).  We  did  not  ﬁnd  any  predictive  factors  for  NIV
ailure  in  the  AECOPD  subgroup.
Previous  studies  have  shown  that  NIV  delivered  in  the
ard  is  effective  in  selected  populations  with  reported
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Table  2  Predictive  variables  of  NIV  failure.
Overall  population  (n  =  75)
Clinical  variable  Success
n  =  67
Failure
n  =  8
p  value  Multivariate
analysis
OR
(95%  CI)
Age,  mean  ±  SD  72  ±  11  79  ±  8  0.052† 0.165◦ 1.07  (0.97--1.18)
Sex, n  (%)
Female  29  (43.3%)  5  (62.5%)  0.302‡ NA  NA
Male 38  (56.7%)  3  (37.5%)
pH level  prior  to  NIV,  mean  ±  SD 7.31  ±  0.10  7.21  ±  0.09  0.025† 0.034◦ 0.92  (0.85--0.99)
PaCO2 prior  to  NIV,  mean  ±  SD 70  ±  24 71  ±  15 0.810† NA  NA
Number of  exacerbations  in  the  previous  year,  n  (%)
<2 48  (71.6%)  7  (87.5%)  0.092‡ 0.152◦ 5.8  (0.52--65.6)
≥2 19  (28.4%)  1  (12.5%)
AECOPD  group  (n  =  42)
Clinical  variable Success
n  =  38
Failure
n  =  4
p  value Multivariate
analysis
OR
(95%  CI)
Age,  median  (máx;  mín)  79  (92;  50)  81  (88;  69)  0.440¥ NA  NA
Sex, n  (%)
Female  16  (42.1%)  1  (25%)  0.507‡ NA  NA
Male 22  (57.9%)  3  (75%)
pH level  prior  to  NIV,  mean  ±  SD* 7.29  ±  0.08 7.22  ±  0.09 0.214† NA  NA
PaCO2 prior  to  NIV,  mean  ±  SD* 79  ±  20 82  ±  6  0.516† NA  NA
Number of  exacerbations  in  the  previous  year,  n  (%)
<2 20  (52.6%)  4  (100%)  0.069‡ NA  NA
≥2 18  (47.4%)  0  (0%)
Severity  of  airway  obstruction
Mild  to  moderate  (FEV1  ≥50%)  10  (26.3%)  2  (50%)  0.201‡ NA  NA
Severe to  very  severe  (FEV1  <50%)  23  (60.5%)  1  (25%)
AECOPD, acute exacerbation of chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; NA, not applicable;
NIV, non-invasive ventilation.
* pH values were multiplied for 100. The OR obtained is for pH increments of 0.01.
† T-test student.
‡ Chi-square test.
◦
Logistic regression.
¥ Mann--Whitney test.
success  rates  ranging  between  66%  and  85%.3--8 In  a
Portuguese  study  including  patients  with  severe  AECOPD
treated  in  a  respiratory  ward,  Oliveira  et  al.  obtained  a  high
success  rate  of  NIV  treatment  (82%).3 Improvement  in  arte-
rial  blood  gases  in  the  ﬁrst  24  h  was  a  determinant  factor
for  NIV  outcomes.  On  the  other  hand,  Mclaughlin  et  al.  have
when  choosing  the  appropriate  level  of  monitoring  for  each
patient.
Other  variables  frequently  reported  as  predictors  of  fail-
ure  are  pretreatment  respiratory  rate,  Glasgow  Coma  Score,
Acute  Physiology  and  Chronic  Health  Evaluation  (APACHE  II),
absence  of  early  improvement  in  blood  gases  and  exces-
s 9,10
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Nshown  a  lower  success  rate  (66%)  when  using  ward-based
NIV  with  392  AECOPD  patients.8 However,  these  results  may
reﬂect  differences  in  the  severity  of  respiratory  failure  of
the  patients  concerned  (mean  baseline  pH  of  7.24  versus
7.29  in  our  sample).
The  importance  of  pretreatment  pH  level  as  a  prognostic
marker  of  NIV  effectiveness  in  the  ward  was  ﬁrst  highlighted
by  Plant  et  al.,  who  found  that  patients  whose  pH  was  below
7.30  had  signiﬁcantly  higher  failure  rates  and  in-hospital
mortality.4 Our  data  also  suggest  that  pretreatment  pH  is
a  useful  predictor  of  NIV  failure  and  should  be  considered
r
r
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wive  secretions. Given  the  retrospective  nature  of  our
tudy,  the  fact  that  severity  scores  for  all  patients  were
ot  available  and  the  lack  of  standardized  protocols  guid-
ng  the  use  of  NIV  in  our  hospital,  we  were  not  able  to
valuate  the  impact  of  those  variables  on  the  efﬁcacy  of
IV.
It  is  important  to  note  that  this  is  a  single-center  ret-ospective  study,  where  NIV  was  delivered  by  experienced
espiratory  physicians  and  well-trained  personnel.  Thus,  our
esults  may  not  be  reproducible  in  other  general  hospital
ards.
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We  hope  that  the  present  study  can  ﬁll  a  gap  in  Por-
uguese  published  data,  giving  a  ‘‘real  life’’  picture  of  the
ndications,  outcomes,  complications  and  clinical  variables
ssociated  with  failure  of  NIV  in  non-critical  care  setting.
In  conclusion,  our  results  suggest  that  NIV  can  be  safely
mplemented  in  respiratory  wards  with  a  high  success  rate.
t  is  our  impression  that  successful  implementation  of  NIV
utside  the  RICU/ICU  depends  mostly  on  the  monitoring
apabilities  of  the  ward  and  personnel  resources  available.
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